The 2025 American Thoracic Society (ATS) just wrapped up its annual conference in San Francisco, California. The six-day, ATS International Conference featured a full program of groundbreaking abstracts and insightful sessions. With nearly 14,000 attendees, this is the premier annual event for sleep, critical care, and pulmonary professionals from around the world. 

With such a varied assortment of health experts convening at the conference, we wanted to take a few moments to spotlight some abstracts related to hypertension at the 2025 ATS International Conference. The following represent a small fraction of the thousands of posters presented at the conference.

Assessing Single Versus Double Lung Transplant Outcomes in Patients with Idiopathic Pulmonary Fibrosis with Pulmonary Hypertension – A Look at the New Pulmonary Hypertension Criteria

  • Description: The study investigated the short-term outcomes in patients who received single and double lung transplant stratified by the pulmonary vascular resistance. Patients were stratified into severe (PVR>5) versus non-severe (PVR<5) pulmonary hypertension.
  • Result: Although bilateral lung transplant is superior to single lung transplant, a single lung transplant might be an acceptable option for patients living with idiopathic pulmonary fibrosis with pulmonary hypertension.

Predictors of Quality of Life in Patients with Portopulmonary Hypertension (POPH): The Pulmonary Hypertension Association Registry

  • Description: Portopulmonary hypertension (POPH) refers to pulmonary arterial hypertension occurring alongside portal hypertension. Individuals with severe liver disease often experience dysfunction, which can influence quality of life. The study aimed to identify factors that influence health-related quality of life in patients diagnosed with POPH.
  • Result: The factors identified were being female, having a high BMI, and severe pulmonary hypertension.

Persistence of Pulmonary Hypertension Symptoms After Two PTEs in a Patient with CTEPH

  • Description: Pulmonary endarterectomy (PTE) is often an effective treatment for pulmonary hypertension. This study presented a case of a patient with residual chronic thromboembolic pulmonary hypertension symptoms after two PTEs with pulmonary hypertension medications and anticoagulation.
  • Result: Patients may require interventions like balloon pulmonary angioplasty while continuing medical therapy and anticoagulation if they experience residual pulmonary hypertension symptoms after a repeat PTE.

Anomalous Pulmonary Venous Return Causing Group 1 Pulmonary Hypertension in a 79 Year Old Male

  • Description: This study reported on a case of an elderly patient with a rare, Group 1 pulmonary hypertension caused by anomalous pulmonary venous return.
  • Result: The study underscores the importance of a multidisciplinary approach in managing pulmonary arterial hypertension and highlights the need for heightened awareness of rare conditions that can affect the management and diagnosis of pulmonary hypertension.

Acute Vasoreactivity Testing Among Pulmonary Arterial Hypertension Patients Enrolled in the Pulmonary Hypertension Association Registry

  • Description: Some patients with idiopathic or hereditary pulmonary arterial hypertension have a positive vasoreactivity test during right heart catheterization, and they tend to have positive clinical outcomes. The study examined the differences in outcomes and characteristics in patients who have pulmonary arterial hypertension and underwent vasodilator challenge testing.
  • Result: As the first contemporary analysis of idiopathic pulmonary arterial hypertension and hereditary pulmonary arterial hypertension vasodilator responders in the United States, patients who were vase-responsive were not found to have a mortality benefit compared to non-responders.

Comparison of Methamphetamine to Non-Methamphetamine Pulmonary Arterial Hypertension

  • Description: Methamphetamine-associated pulmonary hypertension is appearing more frequently. With limited data, this study sought to expand upon the concept of if the WHO functional class is as predictive in patients with methamphetamine-associated pulmonary hypertension versus patients without.
  • Result: The patients with methamphetamine-associated pulmonary hypertension had more severe pulmonary hypertension symptoms compared to the non-methamphetamine group, despite the same WHO functional classifications. A different treatment paradigm may be required for methamphetamine-associated pulmonary hypertension.

For a complete listing of presentations, sessions, and abstracts, visit the 2025 ATS International Conference’s official website.

Sign up for alerts and stay informed on the latest published guidelines and conference recaps.

Copyright © 2025 Guideline Central, all rights reserved.